Cargando…

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial

Waning of neutralizing titres along with decline of protection efficacy after the second dose of COVID-19 vaccines was observed, including China-made inactivated vaccines. Efficacy of a heterologous boosting using one dose of a recombinant SARS-CoV-2 fusion protein vaccine (V-01) in inactivated vacc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xuan-Yi, Mahmood, Syed Faisal, Jin, Fang, Cheah, Wee Kooi, Ahmad, Muhammad, Sohail, Mian Amjad, Ahmad, Waheed, Suppan, Vijaya K., Sayeed, Muneeba Ahsan, Luxmi, Shobha, Teo, Aik-Howe, Lee, Li Yuan, Qi, Yang-Yang, Pei, Rong-Juan, Deng, Wei, Xu, Zhong-Hui, Yang, Jia-Ming, Zhang, Yan, Guan, Wu-Xiang, Yu, Xiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347473/ https://www.ncbi.nlm.nih.gov/pubmed/35686572 http://dx.doi.org/10.1080/22221751.2022.2088406

Ejemplares similares

Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants
por: Fan, Shengtao, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment
por: Mungmunpuntipantip, Rujitika, et al.
Publicado: (2023)

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
por: Tukhvatulin, Amir I., et al.
Publicado: (2022)

Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines
por: Liu, Zezhong, et al.
Publicado: (2023)

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants
por: Zhong, Jiaying, et al.
Publicado: (2022)

Heterologous COVID-19 vaccination in pregnant women: Comment
por: Sookaromdee, Pathum, et al.
Publicado: (2023)

A preliminary study on the effectiveness of maternal to neonatal transfer of antibodies against SARS-CoV-2 in the women vaccinated with heterologous CoronaVac–ChAdOx1
por: Pongsatha, Saipin, et al.
Publicado: (2023)

Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
por: Zhang, Xiaoyin, et al.
Publicado: (2023)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Willingness of college students to receive COVID-19 heterologous vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Heterologous mRNA-based COVID-19 booster strategies: Comment
por: Yasri, Sora, et al.
Publicado: (2023)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
por: Kyaw, Moe H., et al.
Publicado: (2023)

Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China
por: Shao, Hui, et al.
Publicado: (2023)

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
por: Jin, Lairun, et al.
Publicado: (2022)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Author reply to “Heterologous mRNA-based COVID-19 booster strategies: Comment”
por: Das, Rituparna, et al.
Publicado: (2023)

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
por: Das, Rituparna, et al.
Publicado: (2023)

Aggravated pneumonia and diabetes in SARS-CoV-2 infected diabetic mice
por: Huang, Qing, et al.
Publicado: (2023)

Betacoronaviruses SARS-CoV-2 and HCoV-OC43 infections in IGROV-1 cell line require aryl hydrocarbon receptor
por: Yousefi, Meisam, et al.
Publicado: (2023)

Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants
por: Wang, Fengze, et al.
Publicado: (2022)

Comparative global B cell receptor repertoire difference induced by SARS-CoV-2 infection or vaccination via single-cell V(D)J sequencing
por: He, Bing, et al.
Publicado: (2022)

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
por: Liang, Huang, et al.
Publicado: (2022)

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022)

RT-LAMP assay for rapid detection of the R203M mutation in SARS-CoV-2 Delta variant
por: Yang, Jianing, et al.
Publicado: (2022)

hnRNP C modulates MERS-CoV and SARS-CoV-2 replication by governing the expression of a subset of circRNAs and cognitive mRNAs
por: Zhang, Xi, et al.
Publicado: (2022)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
por: Wei, Dong, et al.
Publicado: (2022)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveller returning from overseas
por: Jia, Hongling, et al.
Publicado: (2022)

MERS-CoV nsp1 regulates autophagic flux via mTOR signalling and dysfunctional lysosomes
por: Feng, Yujie, et al.
Publicado: (2022)

Susceptibility of rabbits to SARS-CoV-2
por: Mykytyn, Anna Z., et al.
Publicado: (2021)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
por: Xu, Shiqi, et al.
Publicado: (2022)

The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2
por: Tian, Xiaolong, et al.
Publicado: (2022)

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection
por: Ye, Zi-Wei, et al.
Publicado: (2021)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients: SARS-CoV-2 infection impairs islet function
por: Ji, Ningfei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2i815vra16kqbvrr1158tb7pgl